Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD

Michel P. Hermans*

Cliniques Universitaires St-Luc, Service d’Endocrinologie et Nutrition, Brussels, Belgium

Abstract: Given evidence of increasing prevalence in developed and developing countries, as a result of obesity trends and sedentary lifestyles, the metabolic syndrome represents an increasing burden on healthcare systems. Management guidelines for dyslipidaemia have primarily focused on LDL-C reduction; however, this approach fails to sufficiently address other lipid abnormalities associated with the metabolic syndrome. Atherogenic dyslipidaemia (characterized by elevated triglycerides and low HDL-C) is strongly associated with insulin-resistant states, such as type 2 diabetes and the metabolic syndrome, and is also a common finding among patients receiving treatment for dyslipidaemia. Intervening against atherogenic dyslipidaemia may address a substantial modifiable fraction of residual cardiovascular risk that remains after treatment with a statin. Recent findings from the Fenofoibrate Intervention and Event Lowering in Diabetes (FIELD) study support this view. Fenofibrate treatment was shown to be especially effective in treating marked atherogenic dyslipidaemia, with a significant 27% relative risk reduction for cardiovascular events (P=0.0005, vs. 11%, P=0.035 for all patients) relative to placebo. These data, together with the earlier demonstration of significant microvascular benefits associated with this treatment, suggest a role for fenofibrate, in addition to statin therapy and lifestyle intervention, for reducing global vascular risk in type 2 diabetes patients and for impacting atherogenic dyslipidaemia associated with the metabolic syndrome.

Keywords: Metabolic syndrome, cardiovascular risk, PPARα agonists, fenofibrate, type 2 diabetes.

INTRODUCTION

While mortality rates from cardiovascular disease have declined in recent decades, global trends including increasing prevalence of type 2 diabetes and the continuing tendency towards the adoption of sedentary lifestyles and high-energy diets in developing countries, threaten to slow or even reverse this progress. There is no doubt that aggressive multifactorial intervention to address cardiometabolic risk factors can have a major impact on the risk of adverse cardiovascular outcomes, and continuing research will refine our ideas on how, when and to whom to apply such interventions. This is especially relevant for individuals with type 2 diabetes and/or the metabolic syndrome. Recent analyses from the large Fenofobrate Intervention and Event Lowering in Diabetes (FIELD) study have shed new light on the management of cardiovascular risk in this population. This review examines these new data in the light of the management of cardiovascular risk in patients with type 2 diabetes and features of the metabolic syndrome.

CURRENT FOCUS OF LIPID-MODIFYING THERAPY

Current guidelines for the management of the lipid profile continue to strongly focus on the control of cholesterol associated with the major circulating atherogenic lipoprotein (i.e. apolipoprotein B100 [ApoB]-containing lipoproteins, mostly low-density lipoproteins [LDL] and/or of total cholesterol). The US National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) recommends that “LDL-cholesterol (LDL-C) be the primary target of therapy [1].” Goals for LDL-C are provided for different risk categories: <100 mg/dL (2.6 mmol/L) for patients with coronary heart disease (CHD) or CHD equivalents (such as type 2 diabetes), <130 mg/dL (3.4 mmol/L) for patients with two or more standard cardiovascular risk factors, and <160 mg/dL (4.1 mmol/L) for patients with no more than one cardiovascular risk factor. The guidelines from the European Society of Cardiology (ESC) recommend management of cholesterol within the broader framework of global cardiovascular risk, including overweight, obesity, hypertension and smoking, with cholesterol goals <5 mmol/L (about 190 mg/dL) for total cholesterol and <3 mmol/L (about 115 mg/dL) for LDL-C in low-risk patients [2]. Again, there are more stringent goals for patients in higher cardiovascular risk categories of <4.5 mmol/L (about 155-175 mg/dL) and 2.5 mmol/L (about 80-100 mg/dL) where feasible.

Non-HDL-C (the combined cholesterol load from very low-density lipoproteins [VLDL], intermediate-density lipoproteins [IDL], LDL and other remnants) was proposed as secondary target for therapy beyond LDL-C in the NCEP/ATPIII guidelines for people with triglycerides ≥2.3 mmol/L (≥200 mg/dL) [1]. One rationale was that as triglycerides rise, LDL-C estimation using Friedewald’s formula tends to underestimate the true levels of LDL-C. Another is that non-HDL-C provides additional information on the level of all atherogenic lipoproteins, including those of intermediate size generated during ongoing triglycerides removal (such as IDL) and other ApoB-containing remnants.
and correlates closely with ApoB levels. In addition, these guidelines provide some support for intervention to correct atherogenic dyslipidaemia (low HDL-C and/or high triglycerides), with primary emphasis on lifestyle intervention. HDL-C <1.03 mmol/L (40 mg/dL) and <1.29 (50 mg/dL) is recognized as 'too low' for men and women, respectively, although no specific goal value for raising this parameter was identified as target for therapy. Similarly, European guidelines for cardiovascular risk reduction do not propose goal values for HDL-C or triglycerides [2].

In practice, control of LDL-C usually means intervention with a statin (occasionally combined with ezetimibe) where lifestyle interventions (diet and exercise) are insufficiently effective. There is no doubt that this strategy has delivered substantial reductions in the risk for cardiovascular events in at-risk populations, both in primary and secondary cardiovascular prevention. Large prospective studies have demonstrated relative reductions in risk of cardiovascular events of 20–50% depending on the baseline level of risk [3].

**ATHEROGENIC DYSLIPIDAEMIA, METABOLIC SYNDROME AND CARDIOVASCULAR RISK**

**Diagnosing the Metabolic Syndrome**

The metabolic syndrome represents both an important source as well as an estimate of global cardiovascular risk in addition to hypercholesterolaemia and other standard risk factors, such as smoking and familial cardiovascular history. The condition describes a clustering of cardiovascular risk factors in patients with insulin-resistant states, including obesity, hypertension, coronary heart disease and/or type 2 diabetes. The most commonly-used diagnostic criteria for the metabolic syndrome have been proposed jointly by various scientific bodies, such as the NCEP/ATPIII, the American Heart Association (AHA/NHLBI) [1, 4], and the International Diabetes Federation (IDF) [5]. Each presents a set of five individual criteria based on levels of (or specific treatment for) waist circumference, HDL-C, triglycerides, fasting glucose and blood pressure, and requires the presence of three or more of these five easily-obtained anthropometric or biochemical cardiovascular risk factors to support a diagnosis of the metabolic syndrome.

The main difference between these definitions in terms of practical diagnosis is that meeting any three criteria is sufficient to support the diagnosis of metabolic syndrome according to the NCEP/ATPIII or the AHA/NHLBI, while the IDF require abdominal obesity (high waist circumference) as *sine qua non* criterion plus two or more other criteria. In addition, the IDF provide lower and ethnic-specific cut-offs for waist circumference relative to the NCEP/ATPIII. Other differences include lower cut-off values for fasting glucose (although a threshold of 100 mg/dL was subsequently endorsed by other definitions), and the inclusion of treatment for any specific abnormality in addition to absolute levels of metabolic parameters, in the IDF criteria.

**High Prevalence of Metabolic Syndrome in Type 2 Diabetes Patients**

The prevalence of the metabolic syndrome in non-diabetic patients in western countries is in the region of 25–35%, depending on the diagnostic criteria used [6-8]. However, prevalence appears to be considerably higher in patients with type 2 diabetes. For example, about 80% of type 2 diabetes patients from Finland or Sweden in the Botnia cohort had metabolic syndrome [6]. Additionally, high prevalence rates of NCEP/ATPIII metabolic syndrome have been demonstrated among the populations of major clinical trials in exclusively type 2 diabetes populations, such as the United Kingdom Prospective Diabetes Study (UKPDS) (61%) [9], and the FIELD study (>80%), the latter population being largely without cardiovascular disease at baseline [10].

These observations are consistent with the underlying pathology of type 2 diabetes. Patients with type 2 diabetes meet the diagnostic criterion relating to hyperglycaemia, by definition. In addition, both hypertension and an atherogenic dyslipidaemia phenotype (characterized by low HDL-C, elevated triglycerides and an increase in small, dense LDL), are associated strongly with insulin resistance and compensatory hyperinsulinaemia. These abnormalities are the hallmark of many insulin-resistant states, such as the metabolic syndrome and the common form of type 2 diabetes [11, 12]. A survey conducted in >8000 patients receiving treatment for dyslipidaemia, (mostly with a statin) in 11 European countries confirmed a higher prevalence of low HDL-C and/or hypertriglyceridaemia in patients with type 2 diabetes, relative to patients without diabetes (Table 1) [13, 14].

**Table 1. Prevalence of Features of Atherogenic Dyslipidaemia in Patients With or Without Type 2 Diabetes (T2D) in a Survey Conducted in 11 European Countries**

|                | Men T2D (%) | Men No T2D (%) | Women T2D (%) | Women No T2D (%) |
|----------------|-------------|----------------|---------------|------------------|
| Low HDL-C      | 38          | 29             | 50            | 30               |
| High TG        | 55          | 43             | 54            | 35               |
| Low HDL-C and high TG | 27          | 18             | 34            | 17               |

National Cholesterol Education Program/Adult Treatment Panel III cut-off values used to determine low or high lipid parameters. Type 2 diabetes was present in 3866 patients and absent in 4436 patients. HDL-C: high-density lipoprotein cholesterol; TG: triglycerides. Data from Bruckert et al. [13,14].

**Metabolic Syndrome and Adverse Cardiovascular Outcomes**

A number of studies have associated the metabolic syndrome significantly and independently with an increased risk for type 2 diabetes or cardiovascular disease [15-18]. Importantly, the presence of the metabolic syndrome accentuates cardiovascular risk associated with type 2 diabetes, seemingly above the summative risk afforded by its discrete components. An analysis from the Botnia cohort illustrates this point. Within a cohort of 4483 subjects aged 35–70 years, the prevalence of the metabolic syndrome (diagnosed
using alternative criteria from the World Health Organisa-
tion) increased the risk of pre-existing coronary heart
disease in patients with normal glucose homeostasis or with
pre-diabetic states (impaired fasting glucose and/or impaired
glucose tolerance), or a clinical diagnosis of type 2 diabetes
(Fig. 1). The presence of the metabolic syndrome also
increased the risk of stroke by about 2-fold in the overall
population (P<0.001), although increases in relative risk
associated with the metabolic syndrome did not achieve
statistical significance after stratification of the population
for glycaemic status.

Fig. (1). Impact of the metabolic syndrome on the risk of
cardiovascular disease according to glycaemic status in the Botnia
Study. Coronary heart disease (CHD) was defined as use of nitroglycerine
or prior myocardial infarction (MI). Relative risks were adjusted for
age and gender. IFG: impaired fasting glucose; IGT: impaired
glucose tolerance. Drawn from data presented by Isomaa et al. [6].

Longitudinal data confirm the strong association between
the metabolic syndrome and adverse cardiovascular out-
comes in patients with type 2 diabetes. A post-hoc analysis
from the UKPDS studied the incidence of micro- and
macrovascular complications with respect to baseline
metabolic syndrome in a subset of 4542 newly-diagnosed
type 2 diabetes patients over an average follow-up duration
of 10 years [9]. The risk of macrovascular complications was
markedly and significantly higher in patients with metabolic
syndrome, with increases in the risk of cardiovascular
disease or myocardial infarction of about 30% and an
increase in the risk of stroke of about 70% in patients fulfill-
ing NCCEP/ATPIII criteria. Although the risk of micro-
vascular complications was not captured by metabolic
syndrome identification in the UKPDS, other studies, for
example the Metascreen study [19], have reported an increas-
ed risk of macrovascular and microvascular complications
in type 2 diabetic patients with metabolic syndrome defined
according to AHA/NHLBI or IDF criteria.

In the FIELD study, features of atherogenic dyslipi-
daemia (hypertriglyceridaemia and/or low HDL-C) were
more strongly associated with increased cardiovascular event
rates than the other, non-glycaemic diagnostic criteria
for the metabolic syndrome (Fig. 2). Incident cardiovascular
disease rate increased in line with the number of non-glycaem-
ic metabolic syndrome criteria in addition to type 2 dia-
betes in this study. Relatively little interaction was observed
between high blood pressure and the metabolic syndrome, as
cardiovascular event rates were only about 10% higher in
hypertensive patients with vs. without the metabolic syn-
drome. Similarly, the presence of the metabolic syndrome
increased cardiovascular event rates by about 30% relative to
patients without the metabolic syndrome in patients with
abdominal obesity. However, the greatest impact of the
metabolic syndrome on cardiovascular prognosis was obser-
vied in patients with marked hypertriglyceridaemia (≥2.3
mmol/L or 200 mg/dL) or low HDL-C, where the presence
of the metabolic syndrome increased cardiovascular event
rates by about 2.8-fold and by about 2-fold, respectively.

Whether the metabolic syndrome is itself a driver of
excess cardiovascular risk, or whether the individual risk
factors included in its diagnostic criteria account for all of
the excess adverse cardiovascular outcomes in these patients
is contentious [20, 21]. It is important to note here that the
diagnostic criteria of the metabolic syndrome represent only
a few of the metabolic abnormalities associated with it. A
range of other cardiovascular risk factors also tends to
cluster in patients with the metabolic syndrome, such as a
prothrombotic state, oxidative stress, endothelial dysfunc-
tion, low-grade systemic inflammation and/or albuminuria.
These are all likely to contribute to (or reflect) to a greater or
lesser extent the development (or the burden) of premature
atherosclerotic cardiovascular disease [22].

REducing Cardiovascular RisK in type 2 DIaBeTes PatienTs WITH MetABOlIC
Syndrome

Pathophysiologic Considerations

The data summarized above suggest that the presence of
the metabolic syndrome is likely to be useful in identifying
type 2 diabetes patients at markedly increased cardiovascular
risk who would benefit from intensive intervention [23].
Identifying a metabolic syndrome phenotype may be used
either as a dichotomic state (presence or absence), whereas
score ranking within metabolic syndrome patients may even
represent stepwise rise in cardiovascular risk (from 3/5 to
5/5). The data from the FIELD study, in particular, highlight
atherogenic dyslipidaemia as an important source of modi-
fiable cardiovascular risk in this population. Thus, treatments
which target atherogenic dyslipidaemia and other risk factors
associated with type 2 diabetes and the metabolic syndrome
represent a rational approach to the management of this
population. Peroxisome proliferator activator receptor-α
(PPARα), a nuclear receptor with important transcriptional
regulator activity on lipid metabolism, energy balance and
inflammation, has emerged as a logical target for therapeutic
intervention in metabolic syndrome and type 2 diabetes [24,
25]. As pharmacological agents, fibric acid derivatives exert
their therapeutic action by activating PPARα. Fenofibrate, a
member of this therapeutic class, is a PPARα ligand which has
been shown to increase levels of HDL-C by 10–15% and
to reduce triglycerides by up to 50%, dependent on baseline levels [26-28]. In addition, fenofibrate induces a shift in the subclass distribution of LDL from small, dense LDL to larger particles, usually associated with lesser atherogenic profiles [29, 30].

Fig. (3) shows the effects of fenofibrate, simvastatin and both agents in combination, on these parameters in a 12-week, randomized trial in patients with type 2 diabetes and mixed dyslipidaemia [28, 30]. Fenofibrate was more effective than simvastatin in increasing HDL-C and decreasing triglycerides, and simvastatin was more effective in reducing LDL-C, as would be expected from their mode of action. However, fenofibrate, but not simvastatin, significantly decreased the proportion of LDL in the small, dense (pattern B) subclass, and increased the proportion of larger, more buoyant LDL. Overall, the combination treatment resulted in the least atherogenic lipid profile. These and other studies have also shown that treatment with fenofibrate reduced a series of markers of chronic low-grade systemic inflammation, which have been implicated in the pathogenesis of atherosclerosis or thought of as reflecting its burden [25, 26, 31, 32]. Thus, fenofibrate modulates both key factors and markers of cardiovascular risk associated with the metabolic syndrome that are not adequately addressed by statins.

EXPERIENCE FROM THE FIELD STUDY

Overview of FIELD

In the FIELD study, 9795 patients with type 2 diabetes were randomized to receive treatment with fenofibrate or placebo for an average of 5 years [33, 34]. The study population as a whole was at relatively low cardiovascular risk; patients with an indication for treatment with a statin at baseline were ineligible for the trial, and only 22% had pre-existing cardiovascular disease. Although a reduction of 11% vs. placebo in the primary composite endpoint (nonfatal myocardial infarction or coronary heart disease death) did not achieve statistical significance (hazard ratio [HR] 0.89 [95% CI 0.75 to 0.15], P=0.16), randomization to fenofibrate was associated with significant reductions in the risk of nonfatal myocardial infarction (-24%; HR 0.76 [95% CI 0.62 to 0.94], p=0.01), any cardiovascular disease event (-11%; HR 0.89 [95% CI 0.80 to 0.99], P=0.035), coronary revascularization (-21%; HR 0.79 [95% CI 0.68 to 0.93],...
P=0.003) and any revascularization (-20%; HR 0.80 [95% CI 0.70 to 0.92], p=0.001). A marked reduction in microvascular complications was also observed in the fenofibrate group, including reductions relative to placebo in risk of retinopathy (especially in patients without prior retinopathy), lower-limb non-traumatic amputation, or progression of nephropathy markers [35, 36]. Fenofibrate was well tolerated, with an incidence of side-effects similar to placebo. In particular there was no excess of musculoskeletal serious adverse events with fenofibrate (15% in either group) and only four cases of rhabdomyolysis occurred (one in a patient on placebo and three in patients on fenofibrate, none of whom were receiving a statin).

Patients With Features of the Metabolic Syndrome

The latest analysis from the FIELD study concerns the effects of fenofibrate in patients with cardiovascular risk factors featuring the metabolic syndrome [10]. As expected in a type 2 diabetes population, the proportions of patients who fulfilled diagnostic criteria for NCEP/ATP III metabolic syndrome were high and similar in the placebo (84%) and fenofibrate groups (83%). More women (91%) than men (79%) had the metabolic syndrome at baseline. All patients met the diagnostic criterion relating to hyperglycaemia, as this was an exclusively type 2 diabetes population. More women than men were abdominally obese (83% and 59%, respectively) or had low HDL-C (67% and 55%, respectively); similar proportions of women and men had hypertriglyceridaemia (55% and 50%, respectively) or high blood pressure (86% and 82%, respectively).

The effects of fenofibrate on the risk of incident cardiovascular events in patients stratified for the presence of various features of the metabolic syndrome are shown in Fig. (4). A risk reduction of 11% for fenofibrate vs. placebo in patients with the metabolic syndrome was similar in magnitude to the effect of fenofibrate in the overall population, but marginally failed to reach statistical significance (P=0.052). With regard to individual metabolic syndrome criteria, significant adjusted risk reductions were observed in patients with raised blood pressure and low HDL-C (–12% and -14%, respectively). However, the largest risk reductions occurred in patients with coexisting marked hypertriglyceridaemia and low HDL-C, representing the most comorbid combination in atherogenic dyslipidaemia (-27%, P=0.005). The magnitude of this reduction was in line with the risk reduction observed in landmark statin trials performed in nondiabetic and diabetic cohorts.

CONCLUSIONS

Atherogenic dyslipidaemia is commonly observed among patients under treatment for dyslipidaemia and is an important effector of cardiovascular risk. Recent findings from the FIELD study indicate that not only are type 2 diabetes patients with atherogenic dyslipidaemia at greatest risk for cardiovascular events, but that fenofibrate was most effective in this population. These data, together with the earlier
demonstration of significant microvascular benefits associated with this treatment suggest a role for fenofibrate, in addition to statin therapy and lifestyle intervention, for reducing this residual vascular risk in type 2 diabetes patients with atherogenic dyslipidaemia.

REFERENCES

[1] National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 17: 3143-21.

[2] Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl 2: S1-113.

[3] Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.

[4] Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-8.

[5] International Diabetes Federation. IDF worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/Smet Syndrome_FINAL.pdf (accessed 4 November 2009).

[6] Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.

[7] Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-9.

[8] Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745-9.

[9] Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 2007; 116: 2119-26.

[10] Scott R, O’Brien R, Fulcher G, et al. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 2009; 32: 493-8.

[11] Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med 2003; 4; 228-36.

[12] Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.

[13] Bruckert E, Baccara-Dinet M, Eschwege E. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med 2007; 24: 388-91.

[14] Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005; 21: 1927-34.

[15] Mule G, Cerasola G. The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens 2006; 8: 195-201.

[16] Sarti C, Gallagger J. The metabolic syndrome: prevalence, CHD risk, and treatment. J Diabetes Complications 2006; 20: 121-32.

[17] Ford ES. Risks for all-cause mortality, cardiovascular disease and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-78.

[18] Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.

[19] Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care 2006; 29: 2701-7.

[20] Kahn R, Buse J, Ferramini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American
Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.

[21] Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds J Am Coll Cardiol 2006; 47: 1093-1100.

[22] Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidaemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58: 342-74.

[23] Wong J, Molyneaux L, Constantino MI, Twigg SM, Yue DK. The metabolic syndrome in type 2 diabetes: when does it matter? Diabetes Obes Metab 2006; 8: 690-7.

[24] Plutzky J. PPARs as therapeutic targets: reverse cardiology? Am J Cardiol 2006; 47: 1093-1100.

[25] Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidaemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58: 342-74.

[26] Wong J, Molyneaux L, Constantino MI, Twigg SM, Yue DK. The metabolic syndrome in type 2 diabetes: when does it matter? Diabetes Obes Metab 2006; 8: 690-7.

[27] Keating GM, Croom KF. Fenofibrate. A review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007; 67: 121-53.

[28] Muhlstein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR study. J Am Coll Cardiol 2006; 48: 396-401.

[29] Rizzo M, Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 2007; 23: 1103-11.

[30] May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol 2008; 101: 486-9.

[31] Ziouzenkova O, Perrey S, Asatryan L, et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an anti-inflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA 2003; 100: 2730-5.

[32] Okopić B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006; 91: 1770-8.

[33] FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovasc Diabetol 2004; 3: 9.

[34] FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61.

[35] Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-97.

[36] Rajamani K, Colman PG, Li LP, et al. On behalf of the FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-1788.